An interventional study of Ginkgo biloba and Piracetam in COVID-19, Post COVID-19 Syndrome and Ginkgo Biloba, sponsored by Beni-Suef University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-28.
Sponsored by Beni-Suef University · Not applicable, Interventional, and Treatment
This study aimed to assess functioning during the recovery phase post-COVID-19 and to evaluate symptoms prolonging after COVID-19 infection and how to manage these symptoms.
COVID-19 is a disease caused by a new strain of coronavirus The COVID-19 virus is a new virus linked to the same family of viruses as severe acute respiratory syndrome (SARS) and some types of common cold. Symptoms can include fever, cough, and shortness of breath. In more severe cases, infection can cause pneumonia or breathing difficulties. More rarely, the disease can be fatal. These symptoms are similar to the flu (influenza) or the common cold, which are a lot more common than COVID-19.
The virus is transmitted through direct contact with respiratory droplets of an infected person (generated through coughing and sneezing). Individuals can also be infected from and touching surfaces contaminated with the virus and touching their face (e.g., eyes, nose, mouth).
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 90 is close to the median of 100 across 4,099 interventional studies indexed under COVID-19.
Browse COVID-19 studies →Beni-Suef University is the lead sponsor of 333 studies on the registry; 116 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients who received Ginkgo biloba alone.
Drug: Ginkgo biloba
Patients who received piracetam alone.
Drug: Piracetam
Patients who received a combination (Ginkgo biloba and Piracetam).
Drug: Ginkgo biloba and Piracetam
Patients who received Ginkgo biloba alone.
Patients who received piracetam alone.
Patients who received a combination (Ginkgo biloba and Piracetam).
Mini-Mental State Examination (MMSE)
The Mini-Mental State Examination (MMSE) was used to assess global cognitive status. It evaluates orientation, immediate and delayed recall, attention and calculation, language, and visuospatial construction. The total score ranges from 0 to 30, with higher scores reflecting better cognitive function. Cognitive impairment was classified as mild (21-24), moderate (10-20), or severe (\<10). The MMSE was administered in a face-to-face interview format
Time frame: 1 year after the procedure
Fatigue Severity Scale
Fatigue Severity Scale (FSS) is a validated, widely used self-report instrument designed to quantify the severity and impact of fatigue on daily functioning over the previous seven days. It consists of nine statements covering aspects such as motivation, exercise-induced fatigue, physical functioning, and interference with work, social, and family life. For each item, patients rate their level of agreement on a 7-point scale where 1 indicates strong disagreement and 7 indicates strong agreement. Higher scores on the nine item values (ranging from 1.0 to 7.0) indicate more severe fatigue, with a mean score of 4.0 or higher considered indicative of moderate to severe fatigue. Sum score: total of all item values (9-63). Mean score: average of the 9 item values (1.0-7.0)
Time frame: 1 year after the procedure
Changes in headache severity
Headache by visual analogue scale (VAS) was recorded was recorded at baseline, after 3 months, 6 months, and after 1 year. Pain was assessed by using visual analogue scale (VAS) which is presented as a 10 cm straight line reflecting the extremes of "no pain" and "worst pain. All patients included were followed longitudinally after initiation of treatment, with scheduled follow-up visits for 3 months, 6 months, and 12 months to assess persistence, improvement, or resolution of symptoms.
Time frame: 1 year after the procedure
Prevalence of neurological manifestations
Prevalence of neurological manifestations related to post-COVID syndrome were recorded.
Time frame: 1 year post-procedure
Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Supporting information: Study protocol
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beni-Suef University